earnings
argenx Achieves First Full Year of Profitability with $4.2B in Net Sales (ARGX Q4 2025 Earnings Call)
argenx marked a historic milestone in 2025, delivering its first full year of operating profitability propelled by the staggering success of its flagship immunology drug, VYVGART. The company reported $4.2 billion in global product net sales for the year, representing a 90% year-over-year growth rate. With $1.3 billion of those sales generated in the fourth quarter alone, argenx exited the year with approximately 19,000 patients on treatment globally. Beyond its exceptional financial performance, the company fortified its leadership in FcRn-targeted therapies by announcing positive topline results from its Phase III ADAPT OCULUS study, paving the way for further label expansion into ocular myasthenia gravis.